Skip to content

PK Study of Sildenafil in Neonate

Pharmacokinetic Study of Sildenafil in Neonates and Preterm Infants

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02244528
Enrollment
20
Registered
2014-09-19
Start date
2014-10-31
Completion date
2016-10-31
Last updated
2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonates and Preterm Infants

Brief summary

The purpose of this study is to investigate the pharmacokinetics of sildenafil which is used as treatment of pulmonary hypertension in neonate and preterm infant.

Interventions

DRUGSildenafil

Sponsors

Seoul National University Bundang Hospital
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Months
Healthy volunteers
No

Inclusion criteria

* Admitted at NICU in Seoul National University Hospital or Bundang Seoul National University hospital * Infants who were diagnosed with PAH

Exclusion criteria

* Severe allergic reaction to sildenafil * Inotropics for hypotension within 3 days prior to enrollment * AST or ALT \> 3x ULN * Any condition that would make the participant, in the opinion of the investigator, unsuitable for the stud

Design outcomes

Primary

MeasureTime frameDescription
AUC(0-t)t up to 5 weeks5 times drug level after 5 doses (pre30min/post 30min, 1hr, 2hr, 4hr) pharmacokinetics
Cmax(0-t)t up to 5 weeks5 times drug level after 5 doses (pre30min/post 30min, 1hr, 2hr, 4hr) pharmacokinetics

Secondary

MeasureTime frameDescription
Change from baseline in pulmonary arterial hypertension at 5 weekspre, 2 weeks, 5 weeks of drug administrationEchocardiography * RV systolic pressure: TR velocity2 x 4 * Septum contour: normal, flat at end-systole, flat at end-diastole * LV shape: normal, partially D-shape, D-shape, squeezed * LV eccentricity index * RV area/LV area (Apical 4 chamber view, at end diastole) * RA enlargement (Apical 4 chamber view) * RV anterior wall thickness * TAPSE (Tricuspid annular plane systolic excursion) * RV Tei index (by tissue Doppler) * Tissue Doppler velocity at RV free wall
respiratory severity scorepre, 2 weeks, 5 weeks after administrationMean airway pressure x FiO2

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026